LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

Home・Aandelen Lijst・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Gesloten

SectorGezondheidszorg

26.39 -1.38

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

25.18

Max

26.51

Belangrijke statistieken
By Trading Economics
Inkomsten	-10M -67M
EPS	-1.01
Winstmarge	-7,753.425
Werknemers	186
EBITDA	-9.8M -73M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+104.99% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	307M 1.8B
Vorige openingsprijs	27.77
Vorige sluitingsprijs	26.39

Nieuwssentiment

By Acuity

50%

157 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

18.91 / 20.63 Steun & Weerstand

Celldex Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 dec 2025, 21:41 UTC

Acquisities, Fusies, Overnames

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

26 dec 2025, 20:22 UTC

Marktinformatie

Oil Loses Ground On Russia-Ukraine Peace Efforts -- Market Talk

26 dec 2025, 20:13 UTC

Marktinformatie

U.S. Natural Gas Gains on Colder Weather Outlook -- Market Talk

26 dec 2025, 19:24 UTC

Acquisities, Fusies, Overnames

Nvidia's Groq Deal Is an Instagram Moment -- With 1 Big Risk -- Barrons.com

26 dec 2025, 17:45 UTC

Marktinformatie

U.S. Diesel Down on Lower Crude Prices, Freight-Sector Lull -- Market Talk

26 dec 2025, 15:52 UTC

Marktinformatie

Oil Futures Turn Lower After Steady Start -- Market Talk

26 dec 2025, 14:58 UTC

Marktinformatie

Silver, Gold Reach New Highs Amid Geopolitical Tension -- Market Talk

26 dec 2025, 14:41 UTC

Marktinformatie

U.S. Natural Gas Futures Look to End Week Higher -- Market Talk

26 dec 2025, 14:28 UTC

Marktinformatie

Dollar Indexes Flat as Yen Rally Wanes -- Market Talk

26 dec 2025, 13:47 UTC

Marktinformatie

Oil Futures Steady in Thin Holiday Trade -- Market Talk

26 dec 2025, 07:22 UTC

Marktinformatie

Comex Gold Futures' Strong Bullish Momentum in Play, Chart Shows -- Market Talk

26 dec 2025, 05:03 UTC

Marktinformatie

Malaysian Ringgit Likely to Face Pressure From Dollar Strength in 1Q -- Market Talk

26 dec 2025, 03:38 UTC

Marktinformatie

Global Equities Roundup: Market Talk

26 dec 2025, 03:38 UTC

Marktinformatie

Korean Won Strengthens, Supported by Verbal Interventions -- Market Talk

26 dec 2025, 02:44 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

26 dec 2025, 02:44 UTC

Marktinformatie

Singapore Dollar Weakens Slightly on Likely Position Adjustments -- Market Talk

26 dec 2025, 01:39 UTC

Marktinformatie

China's Central Bank Signals Possibility of Easing Policy in Coming Months -- Market Talk

26 dec 2025, 01:14 UTC

Marktinformatie

Oil Edges Higher Amid Geopolitical Tensions -- Market Talk

26 dec 2025, 00:34 UTC

Marktinformatie

Yen Mostly Weakens Amid Risk-on Sentiment -- Market Talk

26 dec 2025, 00:15 UTC

Marktinformatie

Nikkei Gains 0.6%, Led by Tech, Videogame Stocks -- Market Talk

25 dec 2025, 23:42 UTC

Marktinformatie

Nikkei May Trade in Range; Yen in Focus -- Market Talk

25 dec 2025, 23:40 UTC

Marktinformatie

Gold Edges Higher Amid Geopolitical Risks -- Market Talk

25 dec 2025, 00:20 UTC

Acquisities, Fusies, Overnames

Nike Climb Boosts Dow, S&P 500 -- 2nd Update

24 dec 2025, 22:22 UTC

Acquisities, Fusies, Overnames

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

24 dec 2025, 21:26 UTC

Acquisities, Fusies, Overnames

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

24 dec 2025, 19:35 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

24 dec 2025, 19:35 UTC

Marktinformatie

Treasury Yields Decline Ahead of Christmas -- Market Talk

24 dec 2025, 19:09 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Global Equities Roundup: Market Talk

24 dec 2025, 19:09 UTC

Marktinformatie

Acquisities, Fusies, Overnames

ServiceNow's Armis Acquisition Shouldn't Fuel Fears That Seat-Based Model Threatened -- Market Talk

24 dec 2025, 19:06 UTC

Marktinformatie

Oil Futures Little Changed in Light Pre-Holiday Trade -- Market Talk

Peer Vergelijking

Prijswijziging

Celldex Therapeutics Inc Prognose

Koersdoel

By TipRanks

104.99% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 55 USD 104.99%

Hoogste 90 USD

Laagste 24 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Celldex Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Gebaseerd op 10 analisten die aandelenratings hebben gegeven aan Celldex Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

18.91 / 20.63Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

157 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.